Hydroxyapatite has already been considered as an excellent medical biomaterial.and nanometer hydroxyapatite possesses special characteristics.Hydroxyapatite nanoparticles can inhibit the growth of a wide range of cancer cells.but have no effect on normal cells.thus it has a better selectivity in the treatment of cancer.The anti-tumor mechanism of nano-hydroxyapatite is relevant on the following factors:role in the cell membrane,affecting DNA synthesis,inducing cell cycle blockage and apoptosis,impacting the activity of telomerase.This study is designed to introduce the specific structure and characterjstics of nano-hydroxyapatite,analyze the research progress of nano-hydroxyapatite in tumor field.and discuss the possibility of nano-hydroxyapatite as a new anti-cancer drug in clinical application.

Endostatin(ES), the C-terminal fragment of collagen XVIII, is a potent angiogenesis inhibitor. At present, there are a large number of research papers on ES. It has already been on clinical stage Ⅱ and been widely used in inhibition of neovascularization(NV). However, how to improve the bioactivity of ES is still a matter of ongoing discussion. The objective of this review is to elucidate the relationship between the modified ES and ocular neovascualrization, and to discuss the superiority based on the structure modification. The structure can be changed either by covalent modification or by genetical mutation. It is proposed that the secondary structral ES enhance the anti-angiogenic activity. Studies on modified ES also shed light on our understanding of the molecular action mechanisms of ES. Modified ES may be exploited as a new angiogenesis inhibitor for therapeutic applica-tions, in substitution of the native ES. Activity

Animals ; Carnitine ; pharmacology ; H(+)-K(+)-Exchanging ATPase ; metabolism ; Mitochondria, Muscle ; enzymology ; Muscle, Skeletal ; drug effects ; Physical Conditioning, Animal ; Rats

Child ; Hemangioma ; Humans ; Intestine, Small ; Male

Objective:To analyze the improvement effect of smart drugs shelves on the service process in the outpatient pharmacy and to provide supporting data for the new service process. Methods:The dispensing time of pharmacists and the waiting time of pa-tients were studied and compared before and after the use of smart drugs shelves. Results: After the use of smart drugs shelves, 71. 52% of dispensing time was in 5min, and more than 95% was in 10min. In the 9 periods, the medians of patient waiting time on Oct 21, 2013 were all shorter than those on Oct 18, 2010. Conclusion:The use of smart drugs shelves can improve service efficiency, shorten patient waiting time and enhance service level of outpatient pharmacy.

The chemical constituents from the n-butanol fraction of ethanol extract of safflower (Carthamus tinctorius L.) were isolated and purified using chromatographic process including MCI Gel CHP-20, ODS, Sephadex LH-20 column chromatography, and semi-preparative HPLC method, and one alkyne and two phenylpropanoid derivants were obtained. Their structures were identified as (5R,E)-tetradecane-12-ene-8,10-diyne-1,5,14-triol (1), (E)-8-O-β-D-glucopyranosyl n-butyl cinnamate (2), and (7S,8S)-7-(4-hydroxy-3-methoxybenzene)-7-butyl-8,9-diol (3) by modern spectroscopy methods (1D NMR, 2D NMR, UV, IR and MS). 1-3 are all new compounds. Compounds 1-3 were screened for their anti-renal fibrosis activities in vitro, and none of them showed obvious effect.

Objective To compare the clinical efficacy and carry out analysis on pharmacoeconomic cost-effect of three therapeutic schemes in the treatment for stroke. Methods Through a retrospective survey method, 115 stroke patients, based on different treatment methods, were divided into 3 groups:Xuesaitong group (A), carthamin yellow group (B), and Xueshuantong group (C). An analysis on pharmacoeconomic cost-effect was conducted. Results The costs of three therapeutic schemes were 1030.4 yuan, 1876 yuan, and 1545.6 yuan, respectively. The total effective rates of stroke patients in groups A, B and C were 85.37%, 88.57% and 90.04%, respectively. The cost-effect ratios of groups A, B and C were 12.07, 21.18, and 17.17. The added cost-effect ratios of groups B and C compared with group A were 264.25 and 110.32, respectively. Conclusion Xueshuantong Injection has more pharmacoeconomic advantage than Xuesaitong and carthamin yellow Injections in treating stroke.

OBJECTIVEEctopic atrial tachycardia (EAT) is a common type of supraventricular tachycardia in pediatric population, and it can be resistant to antiarrhythmic drugs and lead to tachycardia induced cardiomyopathy (TIC) if not properly managed. This study assessed the clinical course and response to treatment of EAT in children.

METHODA retrospective review included 144 children at the First Hospital of Tsinghua University diagnosed with EAT from January 2009 to April 2014. The clinical detailed history, 12 lead ECG, 24-h Holter recording, echocardiography, response to therapy and follow-up were analyzed.

RESULTThe onset of EAT occurred at any age with a distribution with positive skewness, 57 children ≤1 years, 22 children > 1 - 3 years, 25 children > 3 - 6 years and 40 children ≥ 6 years of age. The percentages of the three tachycardia types were 36. 1% (n = 52) for incessant EAT, 52. 8% (n = 76) for paroxysmal EAT and 11. 1% (n = 16) for sporadic EAT, respectively. There were 115 patients received drug therapy in our hospital and in 72 cases the EAT was completely controlled. Antiarrhythmic therapy had been discontinued in 35 children with complete control. Normal sinus rhythm was observed by telemetry or Holter within 4 to 90 days and the mean duration of medical therapy was 310 days (range 15 to 608 days) in these children. The combination of sotalol and propafenone showed better effectiveness for control of children with EAT (54%, 41/76), compared with single sotalol (36%, 24/66) and the combination of amiodarone and metoprolol (30%, 7/23) (χ2 = 6. 296, P = 0. 043). Tachycardia type was able to predict the response to antiarrhythmic drugs for children with EAT, sporadic tachycardia had best control rate on pharmacological therapy compared with paroxysmal tachycardia and incessant tachycardia (94% (15/16) vs. 67% (42/63) vs. 42% (15/36), χ2 = 17. 925, P = 0. 000) . Acute success of radiofrequency ablation (RFA) in children who showed poor response to antiarrhythmic drugs was achieved in 45 of 49 (92%), ultimate success was achieved in 33 of 49 (67%). The incidence of TIC secondary to EAT was 18. 1% (n =26), and left ventricular ejection-fraction (LVEF) returned to normal in 23 children after successful control of EAT ((61 ± 4) % vs. (43 ± 5) %, t = - 10. 036, P = 0. 000). Side effects including abnormal thyroid function (in 3) and abnormal liver function (in 1) occurred in 4 (17%) of 23 children who received amiodarone and disappeared when amiodarone was discontinued.

CONCLUSIONEAT in children predominantly occurred in young infants and children. Incessant EAT comprised a great percentage. The combination of sotalol and propafenone provided the best results for control of children with EAT. RFA should be considered as a preferred treatment for older children who displayed poor response to medical therapy.

Amiodarone ; Anti-Arrhythmia Agents ; Cardiomyopathies ; Catheter Ablation ; Child ; Child, Preschool ; Echocardiography ; Electrocardiography ; Humans ; Infant ; Retrospective Studies ; Sotalol ; Tachycardia, Ectopic Atrial ; drug therapy ; physiopathology ; Tachycardia, Supraventricular ; drug therapy ; Ventricular Function, Left

Hemoglobinuria, Paroxysmal ; therapy ; Humans

Acupuncture Points ; Bloodletting ; instrumentation ; methods ; Humans